Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Obeticholic Acid Ameliorates Valproic Acid–Induced Hepatic Steatosis and Oxidative Stress

Zhibo Gai, Evelin Krajnc, Sophia L. Samodelov, Michele Visentin and Gerd A. Kullak-Ublick
Molecular Pharmacology May 2020, 97 (5) 314-323; DOI: https://doi.org/10.1124/mol.119.118646
Zhibo Gai
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., E.K., S.L.S., M.V., G.A.K.-U.); Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland (E.K.); and Mechanistic Safety, CMO & Patient Safety, Global Drug Development, Novartis Pharma, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evelin Krajnc
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., E.K., S.L.S., M.V., G.A.K.-U.); Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland (E.K.); and Mechanistic Safety, CMO & Patient Safety, Global Drug Development, Novartis Pharma, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophia L. Samodelov
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., E.K., S.L.S., M.V., G.A.K.-U.); Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland (E.K.); and Mechanistic Safety, CMO & Patient Safety, Global Drug Development, Novartis Pharma, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Visentin
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., E.K., S.L.S., M.V., G.A.K.-U.); Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland (E.K.); and Mechanistic Safety, CMO & Patient Safety, Global Drug Development, Novartis Pharma, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerd A. Kullak-Ublick
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., E.K., S.L.S., M.V., G.A.K.-U.); Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland (E.K.); and Mechanistic Safety, CMO & Patient Safety, Global Drug Development, Novartis Pharma, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Body weight and liver function. For each experimental group, body weight (A), serum AST (B), and ALT (C) activity were assessed at the end of the experiment. One-way ANOVA, alpha = 0.001. n = 6 mice/group. ctrl, control.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Differential mRNA expression pattern. Volcano plot (A) and pathway enrichment analysis (B) comparing liver transcriptomes of VPA and VPA + OCA groups. n = 6 mice/group. Real-time RT-PCR of the genuine FXR target genes Shp (C) and for the organic solute transporter β (Ostbeta) (D). One-way ANOVA, alpha = 0.001, followed by Tukey’s post hoc analysis. n = 6 mice/group. ctrl, control.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Hepatic oxidative stress in vivo. NGS-derived heat-map, n = 6 mice/group (A). Real-time RT-PCR of Gpx1, Gpx2, and Gpx6 and the glutathione transferase (Gst) a2. One-way ANOVA, alpha = 0.001, followed by Tukey’s post hoc analysis. n = 6 mice/group. (B–E) Representative staining of 4-HNE, Grp78, and glutamine synthetase staining (F). Scale bar, 100 µm. Adh4, alcohol dehydrogenase 4; Akr1b7, aldo-keto reductase 1b7; Cont, control; Gclm, glutamylcysteine synthetase; GS, glutamine synthetase; Nqo1, NAD(P)H quinone dehydrogenase 1.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Oxidative stress in vitro. Cells were incubated for 24 hours with OCA (2 µM) followed by 24 hours with VPA (2 mM). Real-time RT-PCR of the human oxidative stress-related genes GPX1, glutamate-cysteine ligase regulatory subunit, NAD(P)H quinone dehydrogenase 1 (NQO1), and superoxide dismutase 2 (SOD2). Data are expressed as fold change to the housekeeping gene hypoxanthine phosphoribosyltransferase. One-way ANOVA, alpha = 0.005, followed by Tukey’s post hoc analysis. n = 3 independent experiments. (A–D) Total intracellular ROS level. Data are expressed as percentage of the untreated control. One-way ANOVA, alpha = 0.005, followed by Tukey’s post hoc analysis. n = 3 independent experiments (E). Cytosolic (F) and mitochondrial (G) ROS levels. Cells were exposed to H2O2 as positive control. Data are expressed as ratio between the fluorescent signals at the indicated excitation wavelengths. One-way ANOVA, alpha = 0.005, followed by Tukey’s post hoc analysis. n = 3 independent experiments. Representative cytosolic ROS staining. Scale bar, 50 µm (H). Cont, control; GCLM, glutamylcysteine synthetase.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Hepatic Cyp450 expression in vivo. NGS-derived heat-map, n = 6 mice/group (A). Real-time RT-PCR of Cyp2c39 and Cyp2c44. One-way ANOVA, alpha = 0.001, followed by Tukey’s post hoc analysis. n = 6 mice/group (B and C). Representative Western blotting of Cyp2cs (D), n = 5 mice/group from the same experiment. Representative staining of Cyp2cs. Scale bar, 100 µm (E).

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Lipid accumulation in vivo. NGS-derived heat-map of PPARγ-related genes, n = 6 mice/group (A). Real-time RT-PCR of the acyl-CoA thioesterase 1 (Acot1) and the PPARγ. One-way ANOVA, alpha = 0.001, followed by Tukey’s post hoc analysis. n = 6 mice/group (B and C). Representative hematoxylin and eosin (D), BODIPY 493/503 (E), and macrophage marker MAC387 (F) staining, n = 6 mice/group. ctrl, control. Dgat, Diglyceride acyltransferase; Fabp, fatty-acid-binding protein; Slc, solute carrier; Srebf, sterol regulatory element-binding protein gene.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Data -

      Supplementary Table 1

      Supplementary R Script. EdgeR Bioconductor:  Comparison of OCA + VPA over VPA

      Supplementary Figure 1 - Lipid accumulation in vitro. 


PreviousNext
Back to top

In this issue

Molecular Pharmacology: 97 (5)
Molecular Pharmacology
Vol. 97, Issue 5
1 May 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Obeticholic Acid Ameliorates Valproic Acid–Induced Hepatic Steatosis and Oxidative Stress
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

FXR and Valproic Acid–Induced Liver Injury

Zhibo Gai, Evelin Krajnc, Sophia L. Samodelov, Michele Visentin and Gerd A. Kullak-Ublick
Molecular Pharmacology May 1, 2020, 97 (5) 314-323; DOI: https://doi.org/10.1124/mol.119.118646

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

FXR and Valproic Acid–Induced Liver Injury

Zhibo Gai, Evelin Krajnc, Sophia L. Samodelov, Michele Visentin and Gerd A. Kullak-Ublick
Molecular Pharmacology May 1, 2020, 97 (5) 314-323; DOI: https://doi.org/10.1124/mol.119.118646
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics